Ropeginterferon alfa-2b (Besremi)
Protein / enzyme therapeutic
Evidence outlook
Approved: Essential Thrombocythemia, Polycythemia Vera
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also in development:Myelofibrosis · Phase 3 · investigational in the US
Also approved (2)
- Treatment of polycythaemia vera (use only when conventional therapies are not sufficiently effective or inappropriate)
- Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SURPASS ET NCT04285086 · Essential Thrombocythemia This was a randomized, active-controlled (anagrelide) Phase 3 study with a reasonable sample size (174 patients) testing a genuine clinical endpoint combining blood count control, spleen response, symptoms, and vascular event avoidance, and the drug showed a much higher response rate (43% vs 6%). However, the trial was conducted completely open-label with no blinding of patients or investigators, which leaves it vulnerable to assessment bias despite the otherwise solid comparative design, so it lands as supportive but not top-tier evidence. Registry: NCT04285086 | 3 | Peripheral blood count remission (month 9 and month 12); Improvement or non-progression in disease-related signs (month 9 and month 12); Large symptoms improvement or maintain non-progression (month 9 and month 12); Absence of hemorrhagic or thrombotic events (month 9 and month 12) 2024-11-12 | Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (8)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 2/3 (1)
What this study did
Competitive landscape
Other Type I interferon receptor drugs
Interferon alfa-2b (Intron A), Interferon beta-1b, peginterferon alfa-2a (Pegasys), peginterferon beta-1a, Rebif (interferon beta 1a) and 2 more. Compare all 8 Type I interferon receptor drugs
7 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Essential Thrombocythemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ropeginterferon Alfa-2b (Besremi): this drug | Approved | Protein / enzyme therapeutic | Type I interferon receptor | Partial signal | NCT04285086: Durable modified ELN response at months 9 and 12: 39 (43%) of 91 ropeginterferon alfa-2b vs five (6%) of 83 anagrelide | |
| Interferon Alfa-2b (Intron A) | Approved(overall) | Biologic (subtype unspecified) | Type I interferon receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Interferon Beta-1b | Approved(overall) | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Peginterferon Alfa-2a (Pegasys) | Approved(overall) | — | Type I interferon receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Peginterferon Beta-1a (Plegridy) | Approved(overall) | Biologic (subtype unspecified) | Type I interferon receptor, Interferon beta receptor (type I IFN signaling) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Rebif (interferon Beta 1a) | Approved(overall) | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Bomedemstat | Phase 3 | Small molecule | LSD1 (lysine-specific demethylase 1) | not yet graded | No reviewed efficacy summary in this indication | |
| INCA033989 | Phase 3 | Monoclonal antibody | mutant calreticulin (mutCALR) | not yet graded | No reviewed efficacy summary in this indication | |
| Human Serum Albumin / Interferon Alpha2b Fusion Protein | Phase 1/2(overall) | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Interferon-Beta1 | —(overall) | Biologic (subtype unspecified) | Type I interferon receptor | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(9 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ropeginterferon alfa-2b (Besremi) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
2027 (1)
November 2027 (1)
What to watch
2028 (4)
2029 (2)
2032 (1)
January 2032 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent